Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Key Inclusion Criteria:

   - Age ≥ 18

   - Previously treated with relapsed or refractory disease (refractory defined as not
   responding to a standard regimen or progressing within 6 months of the last course of
   a standard regimen)

   - Disease status requirement:

      - For CLL patients, symptomatic disease that mandates treatment as defined by the
      International Workshop on Chronic Lymphocytic Lymphoma (IWCLL) 2008 criteria

      - For indolent NHL and MCL patients, measurable disease by CT scan defined as at
      least 1 lesion that measures > 2 cm in a single dimension

   - WHO performance status of ≤ 2

   - For men and women of child-bearing potential, willing to use adequate contraception
   (ie, latex condom, cervical cap, diaphragm, abstinence, etc.) for the entire duration
   of the study.

      - For Cohort 7 only: Women of child bearing potential must have 2 negative
      pregnancy tests prior to starting lenalidomide.

   - Able to provide written informed consent

Key Exclusion Criteria:

   - Is not a good candidate to receive any of the drugs administered in the study for a
   given disease (idelalisib, bendamustine, rituximab, ofatumumab, fludarabine,
   everolimus, bortezomib, or chlorambucil), according to the clinical judgment of the
   investigator

   - Patients with atypical immunophenotype with t(11:14) translocation or cyclin D1
   over-expression (CLL patients only)

   - Had radiotherapy, radioimmunotherapy, biological therapy, chemotherapy, or treatment
   with an investigational product within 4-weeks prior to the baseline disease status
   tests

   - Had treatment with a short course of corticosteroids for symptom relief within 1-week
   prior to the baseline disease status tests

   - Has had an allogeneic hematopoietic stem cell transplant

   - Has known active central nervous system involvement of the malignancy

   - Is pregnant or nursing

   - Has active, serious infection requiring systemic therapy. Patients may receive
   prophylactic antibiotics and antiviral therapy at the discretion of the investigator

   - Has absolute neutrophil count (ANC) < 1000/µL, unless it is related to underlying CLL,
   MCL or indolent NHL, the latter documented by > 50% infiltration of bone marrow by
   tumor cells

   - Has platelet count < 75000/µL, unless it is related to underlying CLL, MCL, or iNHL,
   the latter documented by > 50% infiltration of bone marrow by tumor cells

   - Has serum creatinine ≥ 2.0 mg/dL

      - For Cohort 7 only: Has creatinine clearance < 60 mL/min

   - Has serum bilirubin ≥ 2 mg/dL (unless due to Gilbert's syndrome) for patients with
   iNHL or CLL; for patients with MCL, serum bilirubin ≥ 1.5 x upper limit of normal

   - Has serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≥ 2 x upper
   limit of normal

   - Has Child-Pugh Class B or C hepatic impairment

   - Has a positive test for HIV antibodies

   - Has active hepatitis B or C (confirmed by RNA test). Patients with serologic evidence
   of prior exposure are eligible.

   - Prior treatment with idelalisib

Note: Other protocol defined Inclusion/Exclusion criteria may apply.